Related Experiment Video
Updated: May 11, 2026
Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
Published on: June 15, 2016
Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived
Michael T Brady1, Austin Miller, Sheila N Sait
1Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, United States.
Insights
Reducing STAT3 activity in acute myeloid leukemia (AML)-derived dendritic cells (DCs) enhances their ability to stimulate T-cells. This finding suggests improved immunogenicity of AML-DCs after STAT3 inhibition.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in approximately 50% of acute myeloid leukemia (AML) patients.
- STAT3 activation is known to inhibit dendritic cell (DC) differentiation, impacting immune responses.
- Understanding STAT3's role in AML-derived DCs is crucial for developing novel immunotherapies.
Purpose of the Study:
- To investigate the correlation between STAT3 activity, DC maturation, and T-cell stimulation in primary AML-derived DCs.
- To evaluate the impact of STAT3 modulation on the immunogenicity of AML-derived DCs.
- To identify potential therapeutic strategies for enhancing anti-leukemia immune responses.
Main Methods:
- Utilized STAT3 knock-down via shRNAmir in AML-derived DCs.
- Treated AML-derived DCs with arsenic trioxide and other inhibitors (AG490, JSI-124, NSC-74859).
- Assessed DC maturation phenotype and T-cell stimulation capacity.
Main Results:
- STAT3 knock-down significantly increased the ability of AML-derived DCs to stimulate T-cells.
- Treatment with arsenic trioxide promoted a more mature DC phenotype and enhanced T-cell stimulation in AML-DCs.
- Arsenic trioxide had minimal effects on normal DCs, indicating specificity.
- Other tested inhibitors (AG490, JSI-124, NSC-74859) did not yield similar enhancements.
Conclusions:
- Reducing STAT3 activity in AML-derived DCs improves their immunogenicity.
- Arsenic trioxide emerges as a potential agent to enhance DC-mediated anti-leukemia immunity by modulating STAT3.
- Targeting STAT3 in AML DCs offers a promising avenue for cancer immunotherapy.
Abstract:
Signal transducer and activator of transcription (STAT) 3 inhibits dendritic cell (DC) differentiation and is constitutively activated in blasts of approximately half of AML patients. We investigated the correlation between STAT3 activity, DC maturation and the ability to stimulate T-cells in primary acute myeloid leukemia (AML)-derived DCs. STAT3 knock-down by shRNAmir increased the ability of AML-DCs to stimulate T-cells. Treatment of AML-DC with arsenic trioxide, but not AG490, JSI-124 or NSC-74859, led to a more mature phenotype and enhanced T-cell stimulation, while having minimal effect on normal DC. We conclude that AML-DCs have improved immunogenicity after reducing STAT3.
